Category Archives: Medicare

New Taxes Won’t Lower Drug Prices

Prescription drug prices continue to be a hot political issue, with the Trump administration preparing to release an action plan as soon as repeal and replace legislation clears Congress. Mick Mulvaney, who heads the White House budget office and is participating in the talks, floated an idea last week that should quickly be crossed off […]

Read More

MACRA: The Burden of Proof

MACRA:  The Burden of Proof by Carol Monaco The Centers for Medicare and Medicaid Services has released a 2,398-page final rule implementing what is likely the most complex clinician payment program in Medicare’s history, known as the Quality Payment Program, born out of the Medicare Access & CHIP Reauthorization Act of 2015 or MACRA. As MACRA […]

Read More

Far-Reaching Medicare Part B Changes Violate Separation Of Powers — And With CBO’s Blessing

Members of Congress expressed outrage at the Congressional Budget Office during a recent House hearing for assuming that sweeping, untested changes to Medicare will save $34 billion “even before you know what the project is,” Rep. Scott Garrett (R-NJ) said. “There is no cost-benefit analysis, there is no testing done, you don’t even know what […]

Read More

Competition in Medicare Advantage, Part D, and “Extra Help”/ Working together for seniors and taxpayers

Seniors are beginning to get fliers in the mail alerting them to the upcoming open season for enrollment in Medicare Advantage and Medicare Part D prescription drug plans.  Both programs rely on competition and consumer choice to increase options and hold down costs for seniors.  Open season begins October 15 for those planning to enroll […]

Read More

CMS Rule On Biosimilar Payment Could Have Serious Side Effects

The Obama administration and leading members of Congress are clashing over a new Medicare payment rule that could compromise patient care, impede development of a fledgling part of the biologics industry, and make it more difficult to track patient safety issues. At issue is government payment policy for a new class of drugs called “biosimilars”—drugs […]

Read More